| __timestamp | Agios Pharmaceuticals, Inc. | Bio-Techne Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 100371000 | 106352000 |
| Thursday, January 1, 2015 | 141827000 | 144969000 |
| Friday, January 1, 2016 | 220163000 | 162364000 |
| Sunday, January 1, 2017 | 292681000 | 188462000 |
| Monday, January 1, 2018 | 1397000 | 210850000 |
| Tuesday, January 1, 2019 | 1317000 | 240515000 |
| Wednesday, January 1, 2020 | 2805000 | 255497000 |
| Friday, January 1, 2021 | 18777000 | 298182000 |
| Saturday, January 1, 2022 | 1704000 | 349103000 |
| Sunday, January 1, 2023 | 9504000 | 366887000 |
| Monday, January 1, 2024 | 4165000 | 389335000 |
In pursuit of knowledge
In the ever-evolving landscape of biotechnology, understanding cost efficiency is crucial. This analysis delves into the cost of revenue trends for Bio-Techne Corporation and Agios Pharmaceuticals, Inc. from 2014 to 2023. Bio-Techne consistently demonstrates robust cost management, with a steady increase in cost of revenue, peaking at approximately $389 million in 2023. This represents a 266% increase from 2014, showcasing their strategic growth.
Conversely, Agios Pharmaceuticals experienced a volatile trajectory. After a peak in 2017, their cost of revenue plummeted by over 99% in 2018, reflecting strategic shifts or operational challenges. By 2023, Agios showed signs of recovery, yet their cost efficiency remains a focal point for investors.
This comparative analysis highlights the importance of strategic cost management in sustaining growth and competitiveness in the biotech sector.
Cost of Revenue: Key Insights for Novo Nordisk A/S and Agios Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Viatris Inc. and Agios Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Comparison: Insmed Incorporated vs Agios Pharmaceuticals, Inc.
Bio-Techne Corporation vs Exelixis, Inc.: Efficiency in Cost of Revenue Explored
Bio-Techne Corporation vs CRISPR Therapeutics AG: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Bio-Techne Corporation vs Perrigo Company plc
Bio-Techne Corporation vs Xencor, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Catalent, Inc. vs Agios Pharmaceuticals, Inc.
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc.'s Expenses
Cost of Revenue: Key Insights for Agios Pharmaceuticals, Inc. and Evotec SE